Market News Latest

Generalized Anxiety Disorder Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

 Breaking News
  • No posts were found

Generalized Anxiety Disorder Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

July 20
18:26 2021
Generalized Anxiety Disorder Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

Delveinsight Business Research LLP

“Generalized Anxiety Disorder Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Generalized Anxiety Disorder Market.

The Generalized Anxiety Disorder Pipeline report embraces in-depth commercial and clinical assessment of the Generalized Anxiety Disorder pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, mergers, acquisition, funding, designations, and other product-related details.

Generalized Anxiety Disorder Pipeline Analysis

As per DelveInsight assessments, the market size of Generalized Anxiety Disorder (GAD) is expected to increase significantly in the 7MM for the study period, 2017–2030. Among 7MM, the US accounts for the highest market size of Generalized Anxiety Disorder (GAD) in 2017.

Generalized Anxiety Disorder Companies:

  • Bionomics

  • Sage Therapeutics

  • VistaGen Therapeutics

  • Fabre-Kramer Pharmaceuticals

  • Forest Laboratories/ Allergan

And others

Generalized Anxiety Disorder Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Generalized Anxiety Disorder with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Generalized Anxiety Disorder Treatment.

  • Generalized Anxiety Disorder key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Generalized Anxiety Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Generalized Anxiety Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Get FREE sample copy at: https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight

Generalized Anxiety Disorder Therapies Covered in the report include:

  • BNC210 

  • Travivo 

  • SAGE-217

  • PH94B

  • Vilazodone

And many more.

The Generalized Anxiety Disorder market size is expected to increase during the forecast period owing to the launch of upcoming therapies in the 7MM.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Generalized Anxiety Disorder.    

  • In the coming years, the Generalized Anxiety Disorder market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Generalized Anxiety Disorder treatment market. Several potential therapies for Generalized Anxiety Disorder are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Generalized Anxiety Disorder market size in the coming years.  

  • Our in-depth analysis of the Generalized Anxiety Disorder pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Request for Sample @ Generalized Anxiety Disorder Novel Therapies And Emerging Technologies

Table of Content

1. Report Introduction

2. Generalized Anxiety Disorder 

3. Generalized Anxiety Disorder Current Treatment Patterns

4. Generalized Anxiety Disorder – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Generalized Anxiety Disorder Late Stage Products (Phase-III)

7. Generalized Anxiety Disorder Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Generalized Anxiety Disorder Discontinued Products

13. Generalized Anxiety Disorder Product Profiles

14. Generalized Anxiety Disorder Key Companies

15. Generalized Anxiety Disorder Key Products

16. Dormant and Discontinued Products

17. Generalized Anxiety Disorder Unmet Needs

18. Generalized Anxiety Disorder Future Perspectives

19. Generalized Anxiety Disorder Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight

Latest Reports By DelveInsight

Generalized Anxiety Disorder Market Insight

DelveInsight’s “Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Acute Pyelonephritis Market

DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/